Cantor Fitzgerald Keeps $15 Price Objective On Melinta Therapeutics (MLNT), Keeps Buy Rating; Barrons 400 (NYSEARCA:BFOR) Shorts Raised By 1900%

The broker have set price target of $15 on Melinta Therapeutics Inc (MLNT) shares. This is 210.56% from the last stock close price. In a research note sent to investors and clients on Wednesday, 13 March, Cantor Fitzgerald reiterated their Buy rating on shares of MLNT.

Barrons 400 (NYSEARCA:BFOR) had an increase of 1900% in short interest. BFOR’s SI was 2,000 shares in March as released by FINRA. Its up 1900% from 100 shares previously. With 6,500 avg volume, 0 days are for Barrons 400 (NYSEARCA:BFOR)’s short sellers to cover BFOR’s short positions. The ETF increased 0.33% or $0.13 during the last trading session, reaching $40.52. About 6,534 shares traded. Barron's 400 ETF (NYSEARCA:BFOR) has declined 0.02% since March 14, 2018 and is downtrending. It has underperformed by 4.39% the S&P500.

More notable recent Melinta Therapeutics, Inc. (NASDAQ:MLNT) news were published by: Nasdaq.com which released: “Melinta Therapeutics, Inc. (MLNT) Reports Q4 Loss, Tops Revenue Estimates – Nasdaq” on March 13, 2019, also Nasdaq.com with their article: “Melinta Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results – Nasdaq” published on March 13, 2019, Globenewswire.com published: “Melinta Therapeutics Announces One-for-Five Reverse Stock Split – GlobeNewswire” on February 21, 2019. More interesting news about Melinta Therapeutics, Inc. (NASDAQ:MLNT) were released by: Benzinga.com and their article: “5 Stocks Moving In Wednesday’s After-Hours Session – Benzinga” published on March 13, 2019 as well as Seekingalpha.com‘s news article titled: “Melinta closes $75M convertible loan funding; shares down 14% premarket – Seeking Alpha” with publication date: February 25, 2019.

The stock increased 0.62% or $0.03 during the last trading session, reaching $4.83. About 87,677 shares traded. Melinta Therapeutics, Inc. (MLNT) has declined 92.23% since March 14, 2018 and is downtrending. It has underperformed by 96.60% the S&P500. Some Historical MLNT News: 29/05/2018 – Melinta Therapeutics Announces Closing of Underwritten Public Offering and Exercise in Full of Underwriters’ Option to Purcha; 08/05/2018 – Melinta Therapeutics 1Q Loss/Shr 95c; 16/04/2018 – Melinta Therapeutics to Present Detailed Results from Vabomere TANGO Il Trial as well as New In Vitro and In Vivo Findings from Baxdela and Pyrrolocytosine Candidate at ECCMID 2018; 23/04/2018 – MLNT PRESENTS DATA ON VABOMERE TANGO II IN VULNERABLE PATIENTS; 23/04/2018 – MELINTA’S RX-P2382 SHOWED IN VITRO ACTIVITY VS ESKAPE PATHOGENS; 23/05/2018 – MELINTA THERAPEUTICS OFFERING PRICES AT $5.00/SHR; 30/04/2018 – $AKAO plazomicin BSI indication will be first drug under AdCom review for Limited Population Antibacterial Drug (LPAD) pathway, and will have important read-thru to other #antibiotics players; 26/03/2018 – Melinta Therapeutics Presenting at Conference Tomorrow; 08/05/2018 – MELINTA THERAPEUTICS 1Q LOSS/SHR 95C, EST. LOSS/SHR $1.30; 21/05/2018 – MELINTA THERAPEUTICS FILES FOR $75M SHARE OFFERING

Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. The company has market cap of $54.16 million. It offers Baxdela, an antibiotic for the treatment of acute bacterial skin and skin structure infections ; Vabomere, a carbapenem used in treatment of gram-negative infections; Orbactiv, an antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens, as well as Solithromycin, a macrolide antibiotic for the treatment of CABP. It currently has negative earnings. The firm also develops Baxdela that in a Phase III clinical trial for treating community-acquired bacterial pneumonia (CABP)); Fusidic Acid, which is in Phase III clinical trial for treating ABSSSIs; and radezolid, a melinta molecule that is in Phase II clinical trial for dermatological applications, as well as ESKAPE pathogen program, which is in preclinical stage targeting superbugs.

Melinta Therapeutics, Inc. (NASDAQ:MLNT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.